谷歌浏览器插件
订阅小程序
在清言上使用

OP05 Primary Efficacy and Safety of Mirikizumab in Moderate to Severe Crohn’s Disease: Results of the Treat-Through VIVID 1 Study

Journal of Crohn's and colitis(2024)

引用 0|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要